A Canarypox Vector Expressing Cytomegalovirus (CMV) Glycoprotein B Primes for Antibody Responses to a Live Attenuated CMV Vaccine (Towne)
To develop a vaccine against cytomegalovirus (CMV), a canarypox virus (ALVAC) expressing CMV glycoprotein (gB) was evaluated alone or in combination with a live, attenuated CMV vaccine (Towne). Three doses of 106.5 TCID50 of ALVAC-CMV(gB) induced very low neutralizing or ELISA antibodies in most ser...
Gespeichert in:
| Veröffentlicht in: | The Journal of infectious diseases 1999-09, Vol.180 (3), p.843-846 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 846 |
|---|---|
| container_issue | 3 |
| container_start_page | 843 |
| container_title | The Journal of infectious diseases |
| container_volume | 180 |
| creator | Adler, Stuart P. Plotkin, Stanley A. Gonczol, Eva Cadoz, Michel Meric, Claude Wang, Jian Ben Dellamonica, Pierre Best, Al M. Zahradnik, John Pincus, Steve Berencsi, Klara Cox, William I. Gyulai, Zsofia |
| description | To develop a vaccine against cytomegalovirus (CMV), a canarypox virus (ALVAC) expressing CMV glycoprotein (gB) was evaluated alone or in combination with a live, attenuated CMV vaccine (Towne). Three doses of 106.5 TCID50 of ALVAC-CMV(gB) induced very low neutralizing or ELISA antibodies in most seronegative adults. However, to determine whether ALVAC-CMV(gB) could prime for antibody responses, 20 seronegative adults randomly received either 106.8 TCID50 of ALVAC-CMV(gB) or 106.8 TCID50 of ALVAC-RG, expressing the rabies glycoprotein, administered at 0 and 1 month, with all subjects receiving a dose of 103.5 pfu of the Towne vaccine at 90 days. For subjects primed with ALVAC-CMV(gB), neutralizing titers and ELISA antibodies to CMV(gB) developed sooner, were much higher, and persisted longer than for subjects primed with ALVAC-RG. All vaccines were well tolerated. These results demonstrate that ALVAC-CMV(gB) primes the immune system and suggest a combined-vaccine strategy to induce potentially protective levels of neutralizing antibodies. |
| doi_str_mv | 10.1086/314951 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_69946177</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30111096</jstor_id><sourcerecordid>30111096</sourcerecordid><originalsourceid>FETCH-LOGICAL-c520t-4c0bfc2f558ac9ac595dbb84e43b6babc5a6d758ff9ac8b29a49bcd36265d08c3</originalsourceid><addsrcrecordid>eNqFkd1u0zAYhiMEYt2AOwBZCKHtIOCf2LEPS9hWpCIQGhXaieU4zpSS2sF2tvYSuGtcpdoQJxzZ8vv4kb7vzbIXCL5DkLP3BBWCokfZDFFS5owh8jibQYhxjrgQR9lxCGsIYUFY-TQ7QunCSclm2e85qJRVfje4LVgZHZ0H59vBmxA6ewOqXXQbc6N6d9v5MYDT6vPqDFz2O-0G76LpLPgAvvpuYwJo09e5jV3tmh34ZsLgbEjP0QEFlt2tAfMYjR1VNA1IGrBSWnfWgNMrd2fN2bPsSav6YJ4fzpPs-8X5VbXIl18uP1XzZa4phjEvNKxbjVtKudJCaSpoU9e8MAWpWa1qTRVrSsrbNoW8xkIVotYNYZjRBnJNTrK3kzcN8Gs0IcpNF7Tpe2WNG4NkQhQMleV_QVRywTDfg6__Addu9DYNITEmAtKyIA827V0I3rRySGtLi5cIyn2Fcqowga8OtrHemOYvbOosAW8OgApa9a1XVnfhgROII4gT9nLC1iGVeh8TiBCCYq_Jp7wL0Wzvc-V_SlaSksrFj2t5cU0w_Yi5XJA_BKa65A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223905743</pqid></control><display><type>article</type><title>A Canarypox Vector Expressing Cytomegalovirus (CMV) Glycoprotein B Primes for Antibody Responses to a Live Attenuated CMV Vaccine (Towne)</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><creator>Adler, Stuart P. ; Plotkin, Stanley A. ; Gonczol, Eva ; Cadoz, Michel ; Meric, Claude ; Wang, Jian Ben ; Dellamonica, Pierre ; Best, Al M. ; Zahradnik, John ; Pincus, Steve ; Berencsi, Klara ; Cox, William I. ; Gyulai, Zsofia</creator><creatorcontrib>Adler, Stuart P. ; Plotkin, Stanley A. ; Gonczol, Eva ; Cadoz, Michel ; Meric, Claude ; Wang, Jian Ben ; Dellamonica, Pierre ; Best, Al M. ; Zahradnik, John ; Pincus, Steve ; Berencsi, Klara ; Cox, William I. ; Gyulai, Zsofia</creatorcontrib><description>To develop a vaccine against cytomegalovirus (CMV), a canarypox virus (ALVAC) expressing CMV glycoprotein (gB) was evaluated alone or in combination with a live, attenuated CMV vaccine (Towne). Three doses of 106.5 TCID50 of ALVAC-CMV(gB) induced very low neutralizing or ELISA antibodies in most seronegative adults. However, to determine whether ALVAC-CMV(gB) could prime for antibody responses, 20 seronegative adults randomly received either 106.8 TCID50 of ALVAC-CMV(gB) or 106.8 TCID50 of ALVAC-RG, expressing the rabies glycoprotein, administered at 0 and 1 month, with all subjects receiving a dose of 103.5 pfu of the Towne vaccine at 90 days. For subjects primed with ALVAC-CMV(gB), neutralizing titers and ELISA antibodies to CMV(gB) developed sooner, were much higher, and persisted longer than for subjects primed with ALVAC-RG. All vaccines were well tolerated. These results demonstrate that ALVAC-CMV(gB) primes the immune system and suggest a combined-vaccine strategy to induce potentially protective levels of neutralizing antibodies.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1086/314951</identifier><identifier>PMID: 10438376</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Adult ; Antibodies ; Antibodies, Viral - blood ; Antibody Formation ; Antigens ; Avipoxvirus - genetics ; Avipoxvirus - immunology ; Biological and medical sciences ; canarypox virus ; Concise Communications ; Cytomegalovirus ; Cytomegalovirus - genetics ; Cytomegalovirus - immunology ; Cytomegalovirus Infections - immunology ; Cytomegalovirus Infections - prevention & control ; Dosage ; Double-Blind Method ; Enzyme linked immunosorbent assay ; Female ; Fundamental and applied biological sciences. Psychology ; Genetic Vectors ; glycoprotein B ; Glycoproteins ; human cytomegalovirus ; Humans ; Infections ; Male ; Microbiology ; Middle Aged ; Vaccination ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies ; Vaccines, Attenuated - adverse effects ; Vaccines, Attenuated - immunology ; Viral Envelope Proteins - immunology ; Viral Vaccines - adverse effects ; Viral Vaccines - immunology ; Virology ; Viruses ; Volunteerism</subject><ispartof>The Journal of infectious diseases, 1999-09, Vol.180 (3), p.843-846</ispartof><rights>Copyright 1999 Infectious Diseases Society of America</rights><rights>1999 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Sep 1999</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c520t-4c0bfc2f558ac9ac595dbb84e43b6babc5a6d758ff9ac8b29a49bcd36265d08c3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30111096$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30111096$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1918102$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10438376$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adler, Stuart P.</creatorcontrib><creatorcontrib>Plotkin, Stanley A.</creatorcontrib><creatorcontrib>Gonczol, Eva</creatorcontrib><creatorcontrib>Cadoz, Michel</creatorcontrib><creatorcontrib>Meric, Claude</creatorcontrib><creatorcontrib>Wang, Jian Ben</creatorcontrib><creatorcontrib>Dellamonica, Pierre</creatorcontrib><creatorcontrib>Best, Al M.</creatorcontrib><creatorcontrib>Zahradnik, John</creatorcontrib><creatorcontrib>Pincus, Steve</creatorcontrib><creatorcontrib>Berencsi, Klara</creatorcontrib><creatorcontrib>Cox, William I.</creatorcontrib><creatorcontrib>Gyulai, Zsofia</creatorcontrib><title>A Canarypox Vector Expressing Cytomegalovirus (CMV) Glycoprotein B Primes for Antibody Responses to a Live Attenuated CMV Vaccine (Towne)</title><title>The Journal of infectious diseases</title><addtitle>The Journal of Infectious Diseases</addtitle><description>To develop a vaccine against cytomegalovirus (CMV), a canarypox virus (ALVAC) expressing CMV glycoprotein (gB) was evaluated alone or in combination with a live, attenuated CMV vaccine (Towne). Three doses of 106.5 TCID50 of ALVAC-CMV(gB) induced very low neutralizing or ELISA antibodies in most seronegative adults. However, to determine whether ALVAC-CMV(gB) could prime for antibody responses, 20 seronegative adults randomly received either 106.8 TCID50 of ALVAC-CMV(gB) or 106.8 TCID50 of ALVAC-RG, expressing the rabies glycoprotein, administered at 0 and 1 month, with all subjects receiving a dose of 103.5 pfu of the Towne vaccine at 90 days. For subjects primed with ALVAC-CMV(gB), neutralizing titers and ELISA antibodies to CMV(gB) developed sooner, were much higher, and persisted longer than for subjects primed with ALVAC-RG. All vaccines were well tolerated. These results demonstrate that ALVAC-CMV(gB) primes the immune system and suggest a combined-vaccine strategy to induce potentially protective levels of neutralizing antibodies.</description><subject>Adult</subject><subject>Antibodies</subject><subject>Antibodies, Viral - blood</subject><subject>Antibody Formation</subject><subject>Antigens</subject><subject>Avipoxvirus - genetics</subject><subject>Avipoxvirus - immunology</subject><subject>Biological and medical sciences</subject><subject>canarypox virus</subject><subject>Concise Communications</subject><subject>Cytomegalovirus</subject><subject>Cytomegalovirus - genetics</subject><subject>Cytomegalovirus - immunology</subject><subject>Cytomegalovirus Infections - immunology</subject><subject>Cytomegalovirus Infections - prevention & control</subject><subject>Dosage</subject><subject>Double-Blind Method</subject><subject>Enzyme linked immunosorbent assay</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Genetic Vectors</subject><subject>glycoprotein B</subject><subject>Glycoproteins</subject><subject>human cytomegalovirus</subject><subject>Humans</subject><subject>Infections</subject><subject>Male</subject><subject>Microbiology</subject><subject>Middle Aged</subject><subject>Vaccination</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</subject><subject>Vaccines, Attenuated - adverse effects</subject><subject>Vaccines, Attenuated - immunology</subject><subject>Viral Envelope Proteins - immunology</subject><subject>Viral Vaccines - adverse effects</subject><subject>Viral Vaccines - immunology</subject><subject>Virology</subject><subject>Viruses</subject><subject>Volunteerism</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkd1u0zAYhiMEYt2AOwBZCKHtIOCf2LEPS9hWpCIQGhXaieU4zpSS2sF2tvYSuGtcpdoQJxzZ8vv4kb7vzbIXCL5DkLP3BBWCokfZDFFS5owh8jibQYhxjrgQR9lxCGsIYUFY-TQ7QunCSclm2e85qJRVfje4LVgZHZ0H59vBmxA6ewOqXXQbc6N6d9v5MYDT6vPqDFz2O-0G76LpLPgAvvpuYwJo09e5jV3tmh34ZsLgbEjP0QEFlt2tAfMYjR1VNA1IGrBSWnfWgNMrd2fN2bPsSav6YJ4fzpPs-8X5VbXIl18uP1XzZa4phjEvNKxbjVtKudJCaSpoU9e8MAWpWa1qTRVrSsrbNoW8xkIVotYNYZjRBnJNTrK3kzcN8Gs0IcpNF7Tpe2WNG4NkQhQMleV_QVRywTDfg6__Addu9DYNITEmAtKyIA827V0I3rRySGtLi5cIyn2Fcqowga8OtrHemOYvbOosAW8OgApa9a1XVnfhgROII4gT9nLC1iGVeh8TiBCCYq_Jp7wL0Wzvc-V_SlaSksrFj2t5cU0w_Yi5XJA_BKa65A</recordid><startdate>19990901</startdate><enddate>19990901</enddate><creator>Adler, Stuart P.</creator><creator>Plotkin, Stanley A.</creator><creator>Gonczol, Eva</creator><creator>Cadoz, Michel</creator><creator>Meric, Claude</creator><creator>Wang, Jian Ben</creator><creator>Dellamonica, Pierre</creator><creator>Best, Al M.</creator><creator>Zahradnik, John</creator><creator>Pincus, Steve</creator><creator>Berencsi, Klara</creator><creator>Cox, William I.</creator><creator>Gyulai, Zsofia</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>19990901</creationdate><title>A Canarypox Vector Expressing Cytomegalovirus (CMV) Glycoprotein B Primes for Antibody Responses to a Live Attenuated CMV Vaccine (Towne)</title><author>Adler, Stuart P. ; Plotkin, Stanley A. ; Gonczol, Eva ; Cadoz, Michel ; Meric, Claude ; Wang, Jian Ben ; Dellamonica, Pierre ; Best, Al M. ; Zahradnik, John ; Pincus, Steve ; Berencsi, Klara ; Cox, William I. ; Gyulai, Zsofia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c520t-4c0bfc2f558ac9ac595dbb84e43b6babc5a6d758ff9ac8b29a49bcd36265d08c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Adult</topic><topic>Antibodies</topic><topic>Antibodies, Viral - blood</topic><topic>Antibody Formation</topic><topic>Antigens</topic><topic>Avipoxvirus - genetics</topic><topic>Avipoxvirus - immunology</topic><topic>Biological and medical sciences</topic><topic>canarypox virus</topic><topic>Concise Communications</topic><topic>Cytomegalovirus</topic><topic>Cytomegalovirus - genetics</topic><topic>Cytomegalovirus - immunology</topic><topic>Cytomegalovirus Infections - immunology</topic><topic>Cytomegalovirus Infections - prevention & control</topic><topic>Dosage</topic><topic>Double-Blind Method</topic><topic>Enzyme linked immunosorbent assay</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Genetic Vectors</topic><topic>glycoprotein B</topic><topic>Glycoproteins</topic><topic>human cytomegalovirus</topic><topic>Humans</topic><topic>Infections</topic><topic>Male</topic><topic>Microbiology</topic><topic>Middle Aged</topic><topic>Vaccination</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies</topic><topic>Vaccines, Attenuated - adverse effects</topic><topic>Vaccines, Attenuated - immunology</topic><topic>Viral Envelope Proteins - immunology</topic><topic>Viral Vaccines - adverse effects</topic><topic>Viral Vaccines - immunology</topic><topic>Virology</topic><topic>Viruses</topic><topic>Volunteerism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adler, Stuart P.</creatorcontrib><creatorcontrib>Plotkin, Stanley A.</creatorcontrib><creatorcontrib>Gonczol, Eva</creatorcontrib><creatorcontrib>Cadoz, Michel</creatorcontrib><creatorcontrib>Meric, Claude</creatorcontrib><creatorcontrib>Wang, Jian Ben</creatorcontrib><creatorcontrib>Dellamonica, Pierre</creatorcontrib><creatorcontrib>Best, Al M.</creatorcontrib><creatorcontrib>Zahradnik, John</creatorcontrib><creatorcontrib>Pincus, Steve</creatorcontrib><creatorcontrib>Berencsi, Klara</creatorcontrib><creatorcontrib>Cox, William I.</creatorcontrib><creatorcontrib>Gyulai, Zsofia</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adler, Stuart P.</au><au>Plotkin, Stanley A.</au><au>Gonczol, Eva</au><au>Cadoz, Michel</au><au>Meric, Claude</au><au>Wang, Jian Ben</au><au>Dellamonica, Pierre</au><au>Best, Al M.</au><au>Zahradnik, John</au><au>Pincus, Steve</au><au>Berencsi, Klara</au><au>Cox, William I.</au><au>Gyulai, Zsofia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Canarypox Vector Expressing Cytomegalovirus (CMV) Glycoprotein B Primes for Antibody Responses to a Live Attenuated CMV Vaccine (Towne)</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>The Journal of Infectious Diseases</addtitle><date>1999-09-01</date><risdate>1999</risdate><volume>180</volume><issue>3</issue><spage>843</spage><epage>846</epage><pages>843-846</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>To develop a vaccine against cytomegalovirus (CMV), a canarypox virus (ALVAC) expressing CMV glycoprotein (gB) was evaluated alone or in combination with a live, attenuated CMV vaccine (Towne). Three doses of 106.5 TCID50 of ALVAC-CMV(gB) induced very low neutralizing or ELISA antibodies in most seronegative adults. However, to determine whether ALVAC-CMV(gB) could prime for antibody responses, 20 seronegative adults randomly received either 106.8 TCID50 of ALVAC-CMV(gB) or 106.8 TCID50 of ALVAC-RG, expressing the rabies glycoprotein, administered at 0 and 1 month, with all subjects receiving a dose of 103.5 pfu of the Towne vaccine at 90 days. For subjects primed with ALVAC-CMV(gB), neutralizing titers and ELISA antibodies to CMV(gB) developed sooner, were much higher, and persisted longer than for subjects primed with ALVAC-RG. All vaccines were well tolerated. These results demonstrate that ALVAC-CMV(gB) primes the immune system and suggest a combined-vaccine strategy to induce potentially protective levels of neutralizing antibodies.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>10438376</pmid><doi>10.1086/314951</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-1899 |
| ispartof | The Journal of infectious diseases, 1999-09, Vol.180 (3), p.843-846 |
| issn | 0022-1899 1537-6613 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69946177 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE |
| subjects | Adult Antibodies Antibodies, Viral - blood Antibody Formation Antigens Avipoxvirus - genetics Avipoxvirus - immunology Biological and medical sciences canarypox virus Concise Communications Cytomegalovirus Cytomegalovirus - genetics Cytomegalovirus - immunology Cytomegalovirus Infections - immunology Cytomegalovirus Infections - prevention & control Dosage Double-Blind Method Enzyme linked immunosorbent assay Female Fundamental and applied biological sciences. Psychology Genetic Vectors glycoprotein B Glycoproteins human cytomegalovirus Humans Infections Male Microbiology Middle Aged Vaccination Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies Vaccines, Attenuated - adverse effects Vaccines, Attenuated - immunology Viral Envelope Proteins - immunology Viral Vaccines - adverse effects Viral Vaccines - immunology Virology Viruses Volunteerism |
| title | A Canarypox Vector Expressing Cytomegalovirus (CMV) Glycoprotein B Primes for Antibody Responses to a Live Attenuated CMV Vaccine (Towne) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T17%3A34%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Canarypox%20Vector%20Expressing%20Cytomegalovirus%20(CMV)%20Glycoprotein%20B%20Primes%20for%20Antibody%20Responses%20to%20a%20Live%20Attenuated%20CMV%20Vaccine%20(Towne)&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Adler,%20Stuart%20P.&rft.date=1999-09-01&rft.volume=180&rft.issue=3&rft.spage=843&rft.epage=846&rft.pages=843-846&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1086/314951&rft_dat=%3Cjstor_proqu%3E30111096%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223905743&rft_id=info:pmid/10438376&rft_jstor_id=30111096&rfr_iscdi=true |